Area of research
Nephrology · Physiology
Research interest
Research interests include Medicine, Fabry disease, Renal function, Diabetes mellitus, Enzyme replacement therapy, and Internal medicine.
Discordance Between Creatinine-Based and Cystatin C–Based Estimated GFR: Interpretation According to Performance Compared to Measured GFR
CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in Adults
Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community
Performance of GFR Estimating Equations in Young Adults
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry
Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes
Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population
Renal structure in type 2 diabetes: facts and misconceptions
Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen
Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial
Fabry disease revisited: Management and treatment recommendations for adult patients
Biological Variability of Estimated GFR and Albuminuria in CKD
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry
Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry
Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy
Predicting decline of kidney function in lupus nephritis using urine biomarkers
The management and treatment of children with Fabry disease: A United States-based perspective
Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial
Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitus
Cross-Disciplinary Biomarkers Research
Is diabetic nephropathy reversible?
Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients